A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Name: A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Published: 2020
License: https://creativecommons.org/publicdomain/mark/1.0/

Numab Therapeutics AG · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

advanced-solid-tumor carcinoma colorectal-cancer head-and-neck-squamous-cell-carcinoma neoplasms non-small-cell-lung-cancer squamous-cell-carcinoma triple-negative-breast-cancer

This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.

Conceptio Open Archive

Analyze & explore related research in Conceptio

Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.

Explore in Search →Connect via MCP / API ↗

This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗

A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

Analyze & explore related research in Conceptio

Related documents